---
title: "Eton Pharmaceuticals | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 24.27 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286464237.md"
datetime: "2026-05-14T20:33:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286464237.md)
  - [en](https://longbridge.com/en/news/286464237.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286464237.md)
---

# Eton Pharmaceuticals | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 24.27 M

Revenue: As of FY2026 Q1, the actual value is USD 24.27 M, beating the estimate of USD 22.4 M.

EPS: As of FY2026 Q1, the actual value is USD 0.05, missing the estimate of USD 0.09.

EBIT: As of FY2026 Q1, the actual value is USD 3.55 M.

#### Revenue

Total net revenue for the first quarter of 2026 was $24.3 million, representing a 40% increase compared to $17.3 million in the prior year period . Product sales and royalty revenue for Q1 2026 reached $24.3 million, marking a 73% increase from $14.0 million in Q1 2025 . The total net revenue in Q1 2025 included $3.3 million from licensing revenue .

#### Gross Profit

Gross profit for the first quarter of 2026 increased by 49% to $14.7 million, up from $9.9 million in the prior year . Adjusted gross profit for Q1 2026 was $16.2 million, resulting in an adjusted gross margin of 67% . This compares to an adjusted gross profit of $12.0 million and an adjusted gross margin of 69% in Q1 2025 . Eton Pharmaceuticals, Inc. expects its full-year 2026 adjusted gross margin to exceed 70% .

#### Operating Expenses

Research and Development (R&D) expenses for Q1 2026 were $1.9 million, compared to $1.2 million in the prior year period . General and Administrative (G&A) expenses increased by 13% to $10.4 million in Q1 2026, from $9.2 million in Q1 2025 . Adjusted G&A expense was $9.0 million in Q1 2026, compared to $7.3 million in the prior year period .

#### Net Income and Adjusted EBITDA

Eton Pharmaceuticals, Inc. reported a net income of $1.6 million for Q1 2026, or $0.05 per diluted share, a significant improvement from a net loss of - $1.6 million, or - $0.06 per basic and diluted share, in the prior year period . On a non-GAAP basis, net income was $4.5 million, or $0.14 per diluted share, for Q1 2026, up from $2.4 million, or $0.07 per diluted share, in Q1 2025 . Adjusted EBITDA for Q1 2026 was $5.7 million, or 24% of revenue, compared to $3.7 million, or 21% of revenue, in the prior year period .

#### Cash Flow and Position

As of March 31, 2026, cash and cash equivalents were $19.7 million . The company generated $7.4 million from operations during Q1 2026 . Cash flows used in investing activities totaled - $15.075 million, primarily due to the purchase of product licensing rights for - $15.0 million . Net cash from financing activities was $1.389 million .

#### Outlook / Guidance

Eton Pharmaceuticals, Inc. raised its full-year 2026 revenue guidance, now expecting revenues to exceed $120 million, an increase from the previous guidance of $110 million . The company also anticipates reporting at least a 30% Adjusted EBITDA margin for the full year 2026 .

### Related Stocks

- [ETON.US](https://longbridge.com/en/quote/ETON.US.md)

## Related News & Research

- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)
- [Euronext will be ready if demand for 24/7 trading grows, CEO says](https://longbridge.com/en/news/287018262.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)
- [Dine Brands Global declares $0.19 Q2 dividend, approves $100M new buyback](https://longbridge.com/en/news/286416253.md)